MXPA05013756A - Piperazinil-ariloxi y piperazinil-heteroariloxi-n-aril-lactamas novedosas. - Google Patents

Piperazinil-ariloxi y piperazinil-heteroariloxi-n-aril-lactamas novedosas.

Info

Publication number
MXPA05013756A
MXPA05013756A MXPA05013756A MXPA05013756A MXPA05013756A MX PA05013756 A MXPA05013756 A MX PA05013756A MX PA05013756 A MXPA05013756 A MX PA05013756A MX PA05013756 A MXPA05013756 A MX PA05013756A MX PA05013756 A MXPA05013756 A MX PA05013756A
Authority
MX
Mexico
Prior art keywords
piperazinyl
disorder
heteroaryloxy
aryloxy
novel
Prior art date
Application number
MXPA05013756A
Other languages
English (en)
Inventor
Mark Allen Sanner
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of MXPA05013756A publication Critical patent/MXPA05013756A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24—Oxygen or sulfur atoms
    • C07D207/26—2-Pyrrolidones
    • C07D207/273—2-Pyrrolidones with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to other ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D211/72—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D211/74—Oxygen atoms
    • C07D211/76—Oxygen atoms attached in position 2 or 6
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pyrrole Compounds (AREA)

Abstract

La presente invencion se refiere a compuestos de Formula I (ver Formula I) en los que Ar, Y y G son como se definio en la memoria descriptiva, a es 1 a 4, Z y W son carbono o nitrogeno y n es 1, 2 o 3; y a composiciones farmaceuticas que comprenden el compuesto de Formula I y un portador farmaceuticamente eficaz y a un metodo util en el tratamiento o prevencion en mamiferos, incluyendo seres humanos, de un trastorno o afeccion seleccionado/a del grupo que consiste en: ansiedad, depresion, distimia, trastorno depresivo grave, jaqueca, trastorno por estres postraumatico, trastorno de la personalidad por evitacion, trastorno de la personalidad fronteriza y fobias.
MXPA05013756A 2003-06-18 2004-06-07 Piperazinil-ariloxi y piperazinil-heteroariloxi-n-aril-lactamas novedosas. MXPA05013756A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US47943603P 2003-06-18 2003-06-18
PCT/IB2004/001942 WO2004110994A1 (en) 2003-06-18 2004-06-07 Novel piperazinyl-aryloxy and piperazinyl-heteroaryloxy-n-aryl lactams

Publications (1)

Publication Number Publication Date
MXPA05013756A true MXPA05013756A (es) 2006-03-08

Family

ID=33551884

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA05013756A MXPA05013756A (es) 2003-06-18 2004-06-07 Piperazinil-ariloxi y piperazinil-heteroariloxi-n-aril-lactamas novedosas.

Country Status (7)

Country Link
US (1) US7101885B2 (es)
EP (1) EP1638932A1 (es)
JP (1) JP2006527757A (es)
BR (1) BRPI0410561A (es)
CA (1) CA2528644A1 (es)
MX (1) MXPA05013756A (es)
WO (1) WO2004110994A1 (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3997255B2 (ja) 2004-02-13 2007-10-24 ワーナー−ランバート カンパニー リミテッド ライアビリティー カンパニー アンドロゲンレセプターモジュレーター
US7507860B2 (en) 2004-04-13 2009-03-24 Pfizer Inc. Androgen modulators
WO2005102990A1 (en) 2004-04-22 2005-11-03 Warner-Lambert Company Llc Androgen modulators
WO2005113535A2 (en) * 2004-05-21 2005-12-01 Pfizer Products Inc. Pyrazinylmethyl lactam derivatives
MXPA06014473A (es) * 2004-06-25 2007-03-01 Pfizer Prod Inc Piridil piperazinas para el tratamiento de trastornos de sistema nervioso central.
BRPI0513020A (pt) 2004-07-08 2008-04-22 Warner Lambert Co moduladores de andrÈgenio, seus usos, composição farmacêutica, formulação farmacêutica tópica e artigo de fabricação
WO2006106416A1 (en) * 2005-04-08 2006-10-12 Pfizer Products Inc. PYRIDIL-LACTAMS AND THEIR USE 5 -HTl RECEPTORS LIGAN
TW200724139A (en) 2005-05-05 2007-07-01 Warner Lambert Co Androgen modulators
CA2725680A1 (en) 2008-05-30 2009-12-03 Takeda Pharmaceutical Company Limited Heterocyclic compound
US9586900B2 (en) 2012-09-05 2017-03-07 Bristol-Myers Squibb Company Pyrrolone or pyrrolidinone melanin concentrating hormone receptor-1 antagonists
EP2892897A1 (en) * 2012-09-05 2015-07-15 Bristol-Myers Squibb Company Pyrrolone or pyrrolidinone melanin concentrating hormone receptor-1 antagonists
AR092924A1 (es) 2012-10-09 2015-05-06 Sanofi Sa Derivados de pirrolidinona como moduladores de gpr119 para el tratamiento de diabetes, obesidad, dislipidemia y trastornos relacionados
JP6440625B2 (ja) 2012-11-14 2018-12-19 ザ・ジョンズ・ホプキンス・ユニバーシティー 精神分裂病を処置するための方法および組成物
AR099937A1 (es) 2014-04-04 2016-08-31 Sanofi Sa Compuestos de isoindolinona como moduladores de gpr119 para el tratamiento de diabetes, obesidad, dislipidemia y trastornos relacionados
AR099936A1 (es) * 2014-04-04 2016-08-31 Sanofi Sa Heterociclos condensados sustituidos como moduladores de gpr119 para el tratamiento de la diabetes, obesidad, dislipidemia y trastornos relacionados
US9896434B2 (en) 2014-04-04 2018-02-20 Sanofi Substituted indanone compounds as GPR119 modulators for the treatment of diabetes, obesity, dyslipidemia and related disorders
US10112929B2 (en) 2015-03-09 2018-10-30 Bristol-Myers Squibb Company Lactams as inhibitors of rock
CA2995395C (en) 2015-08-31 2024-04-16 Nutramax Laboratories, Inc. Compositions comprising magnolia, phellodendron, theanine and/or whey protein
AR110988A1 (es) 2017-02-21 2019-05-22 Sanofi Sa Compuestos de azetidina como moduladores de gpr119 para el tratamiento de la diabetes, la obesidad, la dislipidemia y trastornos relacionados

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9725931D0 (en) * 1997-12-05 1998-02-04 Smithkline Beecham Plc Novel compounds
TR200200795T2 (tr) * 1999-09-25 2002-07-22 Smithkline Beecham P. L. C. 5-HT1B antagonistleri olarak piperazin türevleri

Also Published As

Publication number Publication date
CA2528644A1 (en) 2004-12-23
WO2004110994A1 (en) 2004-12-23
US20040266781A1 (en) 2004-12-30
JP2006527757A (ja) 2006-12-07
BRPI0410561A (pt) 2006-06-20
US7101885B2 (en) 2006-09-05
EP1638932A1 (en) 2006-03-29

Similar Documents

Publication Publication Date Title
MXPA05013756A (es) Piperazinil-ariloxi y piperazinil-heteroariloxi-n-aril-lactamas novedosas.
MXPA04000622A (es) Pirazolilcarboxanilidas como funguicidas.
EP1478322A4 (en) Beta 2'-OR 3'-HALONUCLEOSIDE
WO2002100845A8 (en) Hv protease inhibitors, compositions containing the same, their pharmaceutical uses and materials for their synthesis
IL160440A (en) Dihydropteridinones, method for producing the same and the use thereof as medicaments
WO2005035525A3 (en) 2-amido-4-aryloxy-1-carbonylpyrrolidine derivatives as inhibitors of serine proteases, particularly hcv ns3-ns4a protease
MXPA03011006A (es) Compuestos de cicloalquil urea benzo-fusionados 1,4-disustituidos.
MX9701893A (es) Nuevos inhibidores de la prostaglandinsintasa.
WO2003087092A3 (en) Inhibitors of serine proteases, particularly hepatitis c virus ns3 - ns4 protease
AU2003301959A1 (en) Substituted cycloalkyl p1' hepatitis c virus inhibitors
DE60214179D1 (de) IMIDAZOi1,2-AöPYRIDIN-DERIVATE ZUR PROPHYLAXE UND BEHANDLUNG VON HERPES-INFEKTIONEN
TW200716556A (en) Methods of synthesizing 6-alkylaminoquinoline derivatives
ATE432278T1 (de) Verbindungen zur behandlung von krankheiten
CY1109906T1 (el) Παραγωγα c3-kyano εποθιλονης
EA199800620A1 (ru) Замещенные n-[(аминоиминометил или аминометил)фенил] пропиламиды
MXPA05013059A (es) Derivados de 2-amino-piridina como agonistas del adrenoceptor beta-2.
MXPA03010724A (es) Compuestos de carbamato y oxamida como inhibidores de la produccion de citocina.
ATE364043T1 (de) Pyrazolo-pyridine für die behandlung von herpes- ansteckungen
MXPA05010440A (es) Amidas del acido isoquinolina-5-sulfonico como inhibidores de la akt (proteina quinasa b).
WO2003099266A3 (en) Acetamides and benzamides that are useful in treating sexual dysfunction
WO2003039480A3 (en) Method of treating disorder related to high cholesterol concentration
TW200505865A (en) Compounds useful for the treatment of diseases
MXPA05012391A (es) Tratamiento de trastornos psicoticos y depresivos.
DE60222899D1 (de) Verbindungen, verfahren und zusammensetzungen für die behandlung von infektionen mit dem rinderdiarrhö-virus (bvdv) und dem hepatitis-c-virus (hcv)
GB0216001D0 (en) Process and composition

Legal Events

Date Code Title Description
FA Abandonment or withdrawal